Today: 10 July 2026
Banco Bradesco Rises 4% After Brazil Inflation Miss, R$7.6B Move
10 July 2026
2 mins read

Banco Bradesco Rises 4% After Brazil Inflation Miss, R$7.6B Move

São Paulo, July 10, 2026, 15:08 (BRT)

Banco Bradesco S.A. preferred stock was up 4.0% at R$18.72 in afternoon trading on Friday. Its common shares rose 4.6% to R$16.42. The R$0.72 moves for both classes of stock lift the bank’s total market value by about R$7.6 billion, based on outstanding share numbers.

The increase was bigger than what a payout change would cause. BBDC4 rose R$0.72, about 2.1x the R$0.3469 gross intermediate interest-on-equity payout Bradesco set for each preferred share. That went ex on July 6. In Brazil, interest on equity is a cash payout to shareholders.

Traders shifted their bets on Brazil’s rate outlook after the latest inflation data. The IPCA consumer-price index climbed 0.16% in June, missing the market’s 0.31% call and dropping from 0.58% in May. Annual inflation slowed to 4.64%, backing calls for another cut in the Selic policy rate.

Bradesco traded ahead of both the main market and two big home rivals in the afternoon.

Share or indexPrice/levelDay changeLead over Ibovespa
Banco Bradesco preferred R$18.72+4.00%1.35 percentage points
Itaú Unibanco preferred (BVMF:ITUB4)R$44.05+3.43%0.78 percentage point
Banco do Brasil (BVMF:BBAS3)R$20.58+2.90%0.25 percentage point
Ibovespa177,315.31+2.65%

Rates dropped hard. Mirae Asset said futures now price in a 90% chance of a quarter-point Selic cut in August, up from 68% on Wednesday. Brazil’s fixed-rate 2029 Treasury bond yield lost 19 basis points to 14.04%. One basis point equals one-hundredth of a percentage point. Gabriel Pestana, senior economist at Genial Investimentos, said the inflation data was “good news for monetary policy.” InfoMoney

Matheus Pizzani, economist at PicPay, said the report “reinforces our expectation of another cut” of 25 basis points and sees the easing cycle taking the Selic to 13.50%. The central bank lowered the rate to 14.25% on June 17. Bloomberg Línea Brasil

Bradesco shares saw a bigger move than Itaú. The bank’s trailing price-to-earnings ratio is still about 23% below Itaú’s. But Bradesco’s operating returns and asset quality are behind too: first-quarter recurring ROAE was 15.8%, compared to Itaú’s 24.8%.

Investor measureBradescoItaúBradesco gap
Trailing price-to-earnings ratio8.33 times10.85 times23% lower
First-quarter recurring ROAE15.8%24.8%9.0 percentage points lower
Loans more than 90 days past due4.2%1.9%2.3 percentage points higher

Bradesco posted a recurring profit of R$6.81 billion for the first quarter, up 16.1%. That’s the ninth straight quarter earnings grew. Its expanded loan book hit R$1.09 trillion, a gain of 8.4%. Credit cost rose to 3.5% on the back of some specific wholesale issues and pricier retail. The bank is set to announce second-quarter numbers August 5, so Friday’s rerating faces a quick check.

The lower-rates trade isn’t locked in. Annual inflation is 4.64%, still above the central bank’s 4.5% limit, and the June number doesn’t include the oil move up to almost $80 a barrel this week. SulAmérica Investimentos chief economist Natalie Victal said policymakers should exercise “maximum caution” given fiscal pressures and the run-up to elections. A new energy price shock or a weaker real could push rate cuts back and keep Bradesco’s loan losses high. InfoMoney

Bulls are looking for two things at once from Friday’s rally: lower rates in Brazil and progress with Bradesco’s fix-up. Shares still trade at a discount, so there’s more upside if the August rate call and Q2 credit numbers come through.

Jerzy Lewandowski is a senior markets editor at TS2.tech covering stocks, artificial intelligence, semiconductors and global financial markets. He studied economics at the University of Warsaw and previously worked in investment analysis before moving into financial journalism. His daily coverage focuses on the trends and events that matter most to investors worldwide.

Stock Market Today

  • Neurocrine Biosciences (NBIX) draws growth interest on earnings, cash flow, outlook
    July 10, 2026, 2:36 PM EDT. Neurocrine Biosciences (NBIX) is getting attention from growth-focused investors. The company shows EPS growth of 36.4% for this year, topping the industry's 19%. Cash flow grew 35.4% year over year, well ahead of the industry's 3.2%. Analysts have raised earnings estimates, pointing to possible stock gains soon. Neurocrine has a high Zacks Growth Score and a good Zacks Rank, backing the growth story here.
American Airlines Faces New Jet Fuel Numbers; Profit Picture Looks Tighter
Previous Story

American Airlines Faces New Jet Fuel Numbers; Profit Picture Looks Tighter

Go toTop